JP2013539369A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013539369A5 JP2013539369A5 JP2013527309A JP2013527309A JP2013539369A5 JP 2013539369 A5 JP2013539369 A5 JP 2013539369A5 JP 2013527309 A JP2013527309 A JP 2013527309A JP 2013527309 A JP2013527309 A JP 2013527309A JP 2013539369 A5 JP2013539369 A5 JP 2013539369A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- antibody
- antigen
- binding fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 71
- 239000012634 fragment Substances 0.000 claims 49
- 239000000427 antigen Substances 0.000 claims 37
- 102000036639 antigens Human genes 0.000 claims 37
- 108091007433 antigens Proteins 0.000 claims 37
- 102000039446 nucleic acids Human genes 0.000 claims 28
- 108020004707 nucleic acids Proteins 0.000 claims 28
- 150000007523 nucleic acids Chemical class 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims 28
- 102000040430 polynucleotide Human genes 0.000 claims 23
- 108091033319 polynucleotide Proteins 0.000 claims 23
- 239000002157 polynucleotide Substances 0.000 claims 23
- 238000006467 substitution reaction Methods 0.000 claims 20
- 239000013598 vector Substances 0.000 claims 14
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 13
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 11
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 10
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 9
- 239000003937 drug carrier Substances 0.000 claims 5
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 claims 4
- 241001465754 Metazoa Species 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000002496 gastric effect Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 241000589989 Helicobacter Species 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 101100222384 Mus musculus Cxcl13 gene Proteins 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000005004 lymphoid follicle Anatomy 0.000 claims 1
- 210000003563 lymphoid tissue Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 210000004877 mucosa Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37967210P | 2010-09-02 | 2010-09-02 | |
| US61/379,672 | 2010-09-02 | ||
| US201161481645P | 2011-05-02 | 2011-05-02 | |
| US61/481,645 | 2011-05-02 | ||
| PCT/US2011/050177 WO2012031099A2 (en) | 2010-09-02 | 2011-09-01 | Anti-cxcl13 antibodies and methods of using the same |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016218182A Division JP2017099379A (ja) | 2010-09-02 | 2016-11-08 | 抗ｃｘｃｌ１３抗体およびそれを用いる方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013539369A JP2013539369A (ja) | 2013-10-24 |
| JP2013539369A5 true JP2013539369A5 (enExample) | 2014-10-16 |
| JP6097690B2 JP6097690B2 (ja) | 2017-03-15 |
Family
ID=45773520
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527309A Active JP6097690B2 (ja) | 2010-09-02 | 2011-09-01 | 抗ｃｘｃｌ１３抗体およびそれを用いる方法 |
| JP2016218182A Withdrawn JP2017099379A (ja) | 2010-09-02 | 2016-11-08 | 抗ｃｘｃｌ１３抗体およびそれを用いる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016218182A Withdrawn JP2017099379A (ja) | 2010-09-02 | 2016-11-08 | 抗ｃｘｃｌ１３抗体およびそれを用いる方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US9963504B2 (enExample) |
| EP (1) | EP2611832B1 (enExample) |
| JP (2) | JP6097690B2 (enExample) |
| KR (1) | KR101862236B1 (enExample) |
| CN (1) | CN103347896B (enExample) |
| AU (1) | AU2011295902B2 (enExample) |
| BR (1) | BR112013005145B1 (enExample) |
| CA (1) | CA2810217C (enExample) |
| DK (1) | DK2611832T3 (enExample) |
| MX (1) | MX353476B (enExample) |
| NZ (1) | NZ608318A (enExample) |
| SG (1) | SG188285A1 (enExample) |
| WO (1) | WO2012031099A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2427212T3 (pl) | 2009-05-08 | 2018-02-28 | Vaccinex, Inc. | Przeciwciała anty cd-100 i sposoby ich zastosowania |
| EP2611832B1 (en) | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| CN103608680A (zh) * | 2010-12-14 | 2014-02-26 | 詹姆士·W·里拉尔德 | 抗cxcl13抗体和抗cxcr5抗体在恶性肿瘤的治疗或检测中的用途 |
| EA029023B1 (ru) | 2011-10-11 | 2018-01-31 | Вэксинекс, Инк. | Применение молекул, связывающих семафорин-4d, для модуляции проницаемости гематоэнцефалического барьера |
| CN104520323B (zh) | 2012-03-02 | 2018-05-04 | 瓦西尼斯公司 | 用于治疗b细胞介导的炎性疾病的方法 |
| US9708601B2 (en) | 2012-04-26 | 2017-07-18 | Vaccinex, Inc. | Fusion proteins to facilitate selection of cells infected with specific immunoglobulin gene recombinant vaccinia virus |
| CN112807427A (zh) * | 2012-06-27 | 2021-05-18 | 吉安特科技公司 | 一种抗-cxcl10抗体在制备用于治疗受试者中的炎性疾病的用途 |
| SG11201504392XA (en) * | 2012-12-07 | 2015-07-30 | Baxter Int | Anti-mif antibody cell migration assay |
| JP6363623B2 (ja) * | 2013-01-31 | 2018-07-25 | ヴァクシネックス， インコーポレイテッド | 免疫グロブリンａのレベルを増大するための方法 |
| CA2902442A1 (en) * | 2013-03-08 | 2014-09-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
| SG10201902380SA (en) | 2013-06-25 | 2019-04-29 | Vaccinex Inc | Use of semaphorin-4d inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases |
| KR20180042449A (ko) * | 2015-09-15 | 2018-04-25 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | T 세포 수용체(tcr) 결합 항체 및 이의 용도 |
| EP4059516A1 (en) | 2016-04-22 | 2022-09-21 | Vaccinex, Inc. | Integral membrane protein display on poxvirus extracellular enveloped virions |
| SG11201900595YA (en) | 2016-08-02 | 2019-02-27 | Vaccinex Inc | Improved methods for producing polynucleotide libraries in vaccinia virus/eukaryotic cells |
| BR112020010753A2 (pt) | 2017-12-01 | 2020-11-24 | The Regents Of The University Of California | anticorpos anti-cxcr5 e composições e usos dos mesmos |
| EA202190647A1 (ru) | 2018-09-17 | 2021-09-09 | Абкуро, Инк. | Антитела к klrg1 |
| MX2021002605A (es) * | 2018-09-18 | 2021-07-21 | I Mab Biopharma Us Ltd | Anticuerpos anti-cxcl13 para el tratamiento de enfermedades autoinmunes y cancer. |
| CA3181985A1 (en) | 2020-06-11 | 2021-12-16 | Simone DIGIOVANNI | Use of cxcl13 binding molecules to promote peripheral nerve regeneration |
| CN115975946A (zh) * | 2022-12-01 | 2023-04-18 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 表达趋化因子cxcl10、cxcl13、ccl19的免疫细胞及其制备方法与应用 |
| CN121652269B (zh) * | 2026-02-05 | 2026-04-17 | 北京中杉金桥生物技术有限公司 | 一种抗人cxcl13兔单克隆抗体、制备方法及其应用 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
| NZ201918A (en) | 1981-09-18 | 1987-04-30 | Genentech Inc | N-terminal methionyl analogues of bovine growth hormone |
| US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| ATE120454T1 (de) | 1988-06-14 | 1995-04-15 | Cetus Oncology Corp | Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus. |
| US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
| EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| ES2284161T3 (es) | 1990-01-12 | 2007-11-01 | Amgen Fremont Inc. | Generacion de anticuerpos xenogenicos. |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| AU654811B2 (en) | 1990-03-20 | 1994-11-24 | Trustees Of Columbia University In The City Of New York, The | Chimeric antibodies with receptor binding ligands in place of their constant region |
| JP3583420B2 (ja) | 1990-10-05 | 2004-11-04 | メダレツクス・インコーポレーテツド | 二特異的試薬を用いた標的免疫化 |
| AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
| ATE218889T1 (de) | 1990-11-09 | 2002-06-15 | Stephen D Gillies | Cytokine immunokonjugate |
| IE921342A1 (en) | 1991-04-26 | 1992-11-04 | Surface Active Ltd | Novel antibodies, and methods for their use |
| FR2686087A1 (fr) | 1992-01-13 | 1993-07-16 | Inst Nat Sante Rech Med | Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications. |
| WO1993017715A1 (en) | 1992-03-05 | 1993-09-16 | Board Of Regents, The University Of Texas System | Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells |
| US5633149A (en) | 1994-12-07 | 1997-05-27 | Incyte Pharmaceuticals, Inc. | Polynucleotide encoding novel chemokine expressed in inflamed adenoid |
| US6692920B1 (en) | 1994-12-07 | 2004-02-17 | Incyte Corporation | Antibodies to a chemokine expressed in inflamed adenoid |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| KR19990022283A (ko) | 1995-06-05 | 1999-03-25 | 벤슨 로버트 에이치. | 인체 케모킨 베타-11 및 인체 케모킨 알파-1 |
| AU4243097A (en) | 1996-09-10 | 1998-04-02 | Schering Corporation | Mammalian chemokines, related reagents |
| US6852508B1 (en) | 1997-02-28 | 2005-02-08 | Genetics Institute, Llc | Chemokine with amino-terminal modifications |
| US6110695A (en) | 1997-12-02 | 2000-08-29 | The Regents Of The University Of California | Modulating the interaction of the chemokine, B Lymphocyte Hemoattractant, and its Receptor, BLR1 |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
| US6723538B2 (en) | 1999-03-11 | 2004-04-20 | Micromet Ag | Bispecific antibody and chemokine receptor constructs |
| US6849425B1 (en) | 1999-10-14 | 2005-02-01 | Ixsys, Inc. | Methods of optimizing antibody variable region binding affinity |
| JP2003530325A (ja) | 2000-03-31 | 2003-10-14 | イーペーエフ ファルマシューティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 好ましくは特異的ケモカインレセプター分析、及びケモカインレセプター／リガンド相互作用の助けによる、腫瘍及び炎症細胞の細胞表面プロテオームの調査、並びに腫瘍疾患及び炎症性疾患の治療のための診断薬及び薬剤 |
| GB2361003A (en) | 2000-04-07 | 2001-10-10 | Astrazeneca Ab | Novel compounds |
| US7052676B2 (en) | 2000-09-26 | 2006-05-30 | The Regents Of The University Of Michigan | Methods for inhibition of HIV replication using a small molecule inhibitor |
| CA2429544C (en) | 2000-11-17 | 2010-10-19 | University Of Rochester | In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells |
| MXPA03004913A (es) | 2000-12-01 | 2003-09-05 | Schering Corp | Usos de genes de mamifero y reactivos relacionados. |
| WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
| US6818406B2 (en) | 2001-03-23 | 2004-11-16 | Mayo Foundation For Medical Education And Research | Rheumatoid arthritis markers |
| US20030020733A1 (en) | 2001-07-24 | 2003-01-30 | Yin Memphis Zhihong | Computer display having selective area magnification |
| US7442512B2 (en) | 2001-11-30 | 2008-10-28 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US7413866B2 (en) | 2001-11-30 | 2008-08-19 | Chemocentryx, Inc. | Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| JP4524181B2 (ja) | 2002-05-30 | 2010-08-11 | マクロジェニクス，インコーポレーテッド | Ｃｄ１６ａ結合タンパク質および免疫障害治療のための使用 |
| EP1576137A4 (en) | 2002-10-29 | 2010-06-30 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| WO2004045526A2 (en) | 2002-11-15 | 2004-06-03 | Morehouse School Of Medicine | Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms |
| US7964194B2 (en) | 2002-11-15 | 2011-06-21 | Morehouse School Of Medicine | Anti-chemokine and associated receptor antibodies and uses for inhibition of inflammation |
| JP2011516026A (ja) | 2002-11-26 | 2011-05-26 | ジェネンテック・インコーポレーテッド | 免疫関連疾患の治療のための組成物と方法 |
| EP1613657A2 (en) * | 2003-03-28 | 2006-01-11 | Centocor, Inc. | Anti-amyloid antibodies, compositions, methods and uses |
| EP1570857A1 (en) | 2004-02-27 | 2005-09-07 | Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO | Method for inhibiting the transendothelal migration of cells such as leukocytes or tumor cells by a CD81 binding agent and uses thereof |
| JP2007532656A (ja) | 2004-04-12 | 2007-11-15 | アメリカ合衆国 | アデノウイルスベクターを用いて免疫応答を誘導するための方法 |
| CA2501422C (en) | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
| CA2544692C (en) * | 2004-07-09 | 2014-04-01 | Chugai Seiyaku Kabushiki Kaisha | Anti-glypican 3 antibody |
| EA200701211A1 (ru) | 2004-12-31 | 2007-12-28 | Дженентек, Инк. | Полипептиды, которые связываются с br3, и их применение |
| ES2707152T3 (es) | 2005-04-15 | 2019-04-02 | Macrogenics Inc | Diacuerpos covalentes y usos de los mismos |
| WO2006117910A1 (ja) | 2005-04-28 | 2006-11-09 | Mochida Pharmaceutical Co., Ltd. | 抗血小板膜糖蛋白質ⅵモノクローナル抗体 |
| WO2007064911A1 (en) * | 2005-12-02 | 2007-06-07 | Biogen Idec Inc. | Anti-mouse cd20 antibodies and uses thereof |
| GB0607774D0 (en) | 2006-04-20 | 2006-05-31 | Renovo Group Plc | Medicaments |
| RU2449808C2 (ru) * | 2006-04-21 | 2012-05-10 | Сентокор, Инк. | Антагонисты cxcl13 и их применение для лечения воспалительных заболеваний |
| US20080227704A1 (en) * | 2006-12-21 | 2008-09-18 | Kamens Joanne S | CXCL13 binding proteins |
| US20080199481A1 (en) * | 2007-02-21 | 2008-08-21 | Astrazeneca Ab | Compounds |
| WO2008121940A1 (en) * | 2007-03-30 | 2008-10-09 | Centocor, Inc. | Cxcl13 antagonists and their use for the treatment of inflammatory diseases |
| US20110300167A1 (en) | 2008-11-04 | 2011-12-08 | Mcmurry Thomas J | Cxcr5 receptor compounds |
| EP2611832B1 (en) | 2010-09-02 | 2017-11-29 | Vaccinex, Inc. | Anti-cxcl13 antibodies and methods of using the same |
| CN104114187A (zh) | 2011-12-28 | 2014-10-22 | 诺沃姆德治疗公司 | 去糖基化的人类抗体、其融合蛋白质及用途 |
| CN104520323B (zh) | 2012-03-02 | 2018-05-04 | 瓦西尼斯公司 | 用于治疗b细胞介导的炎性疾病的方法 |
| JP6363623B2 (ja) | 2013-01-31 | 2018-07-25 | ヴァクシネックス， インコーポレイテッド | 免疫グロブリンａのレベルを増大するための方法 |
| CA2902442A1 (en) | 2013-03-08 | 2014-09-12 | Vaccinex, Inc. | Anti-cxcl13 antibodies and associated epitope sequences |
-
2011
- 2011-09-01 EP EP11822655.4A patent/EP2611832B1/en active Active
- 2011-09-01 SG SG2013013735A patent/SG188285A1/en unknown
- 2011-09-01 JP JP2013527309A patent/JP6097690B2/ja active Active
- 2011-09-01 CA CA2810217A patent/CA2810217C/en active Active
- 2011-09-01 NZ NZ60831811A patent/NZ608318A/en unknown
- 2011-09-01 AU AU2011295902A patent/AU2011295902B2/en active Active
- 2011-09-01 CN CN201180052932.5A patent/CN103347896B/zh active Active
- 2011-09-01 BR BR112013005145-0A patent/BR112013005145B1/pt active IP Right Grant
- 2011-09-01 US US13/820,278 patent/US9963504B2/en active Active
- 2011-09-01 WO PCT/US2011/050177 patent/WO2012031099A2/en not_active Ceased
- 2011-09-01 KR KR1020137008377A patent/KR101862236B1/ko active Active
- 2011-09-01 DK DK11822655.4T patent/DK2611832T3/en active
- 2011-09-01 MX MX2013002495A patent/MX353476B/es active IP Right Grant
-
2016
- 2016-11-08 JP JP2016218182A patent/JP2017099379A/ja not_active Withdrawn
-
2018
- 2018-04-13 US US15/953,139 patent/US10829550B2/en active Active
-
2020
- 2020-09-24 US US17/030,627 patent/US11981730B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516057A5 (enExample) | ||
| ES2573115T3 (es) | Nuevo anticuerpo anti-DR5 | |
| JP7041516B2 (ja) | 共通軽鎖を有する二重特異性抗体又は抗体混合物 | |
| JP2021518140A5 (enExample) | ||
| JP2018121657A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| JP2014518883A5 (enExample) | ||
| JP2013520984A5 (enExample) | ||
| RU2018119366A (ru) | Мыши с гуманизированной легкой цепью | |
| JP2012504401A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| JP2020510422A5 (enExample) | ||
| JP2010246565A5 (enExample) | ||
| JP2012525854A5 (enExample) | ||
| RU2018133708A (ru) | Антитела, обладающие специфичностью к btla, и их использование | |
| JP2016128474A5 (enExample) | ||
| RU2013153592A (ru) | Анти-mif антитела | |
| RU2009126766A (ru) | Антитела человека к дельта-подобному лиганду-4 человека | |
| JP2012526542A5 (enExample) | ||
| JP2017529067A5 (enExample) | ||
| FI3842456T3 (fi) | Monoklonaalinen interleukiini-31-vasta-aine | |
| HRP20150965T1 (hr) | Anti-fgr3 protutijela i metode koje ih koriste | |
| JP2012501669A5 (enExample) | ||
| JP2016526904A5 (enExample) | ||
| RU2010129045A (ru) | Связывающие молекулы к рецептору ох40 человека |